Australia's harm reduction strategies serve as model for other countries, UNAIDS official says

NewsGuard 100/100 Score

The Australian government's efforts to curb the spread of HIV by advocating harm-reduction initiatives, such as needle-exchange programs and drug substitution therapy, for injection drug users serve as a model for other countries throughout the region, UNAIDS Asia Pacific Director Prasada Rao said recently, the AAP/Sydney Morning Herald reports.

Rao said that Australia has called on Asian states to increase harm-reduction programs and examine current drug laws, especially in those states where penalties for drug users can include the death penalty. Rao said, "Australia is a good model for harm reduction programs and also for looking at drug laws and revamping them. In fact, quite a few countries in Asia have learned their harm reduction strategies in good examples from Australia."

Parliamentary Secretary for International Development Assistance Bob McMullan said that it is still possible for countries to adopt effective prevention and harm reduction strategies to combat HIV without encouraging drug use. He said that a "very big important part of the Australian government policy" is working "strongly" with drug users. He added that "in terms of reducing the spread of HIV, we have to focus on prevention." Rao's comments came as McMullan announced an additional 640,000 Australian dollars, or about $470,000, for nongovernmental organizations working in Asia (Corben, AAP/Sydney Morning Herald, 5/3).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common HIV drugs linked to reduced Alzheimer's disease risk